Pfizer Seeks FDA’s OK for Kidney Cancer Drug
Pfizer Inc. said it had asked U.S. regulators for permission to sell its experimental pill against cancers of the kidney and stomach, a product it is counting on to help restore earnings growth.
Pfizer said it had asked the Food and Drug Administration to approve its Sutent pill to treat gastrointestinal stromal tumors, a type of stomach cancer, and kidney cancer that has spread to other parts of the body and has not been controlled by standard treatments.
Shares of Pfizer fell 12 cents to $26.39.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
